# Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis

> **NCT01156025** · PHASE2 · COMPLETED · sponsor: **Laboratoires Thea** · enrollment: 16 (actual)

## Conditions studied

- Acute Adenoviral Keratoconjunctivitis

## Interventions

- **DRUG:** GV550
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01156025
- **Lead sponsor:** Laboratoires Thea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-02
- **Final completion:** 2010-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2010-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01156025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01156025, "Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01156025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*